Nautilus Biotechnolgy
NAUT
82 hedge funds and large institutions have $244M invested in Nautilus Biotechnolgy in 2022 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 21 increasing their positions, 16 reducing their positions, and 16 closing their positions.
537% more call options, than puts
Call options by funds: $586K | Put options by funds: $92K
31% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 16
1% more funds holding
Funds holding: 81 → 82 (+1)
6% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 16
4% more capital invested
Capital invested by funds: $235M → $244M (+$8.74M)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
2.95% less ownership
Funds ownership: 47.97% → 45.03% (-2.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.38M |
| 2 |
TM
Tikvah Management
Charlotte,
North Carolina
|
+$1.06M |
| 3 |
Millennium Management
New York
|
+$1.04M |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
+$566K |
| 5 |
HF
HRT Financial
New York
|
+$456K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$12.6M |
| 2 |
O
OrbiMed
New York
|
-$7.53M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$3.97M |
| 4 |
AAA
Affinity Asset Advisors
New York
|
-$2.01M |
| 5 |
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University
Redwood City,
California
|
-$1.6M |
NAUT Hedge Fund Activity: Q1 2022 in Review
82 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Nautilus Biotechnolgy (NAUT) for Q1 2022, worth a combined $244M — up 3.7% from $235M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new NAUT positions and 16 closed out — a net gain of 1 holder — while 21 added to existing stakes and 16 trimmed.
The largest buyer was Vanguard Group, adding an estimated $4.38M. The largest seller was RA Capital Management, exiting entirely with an estimated $12.6M sold.
- 82 institutional investors held Nautilus Biotechnolgy (NAUT) as of Q1 2022, up from 81 in Q4 2021.
- Funds reported $244M of Nautilus Biotechnolgy stock for Q1 2022, up 3.7% quarter-over-quarter.
- 17 funds opened new Nautilus Biotechnolgy positions in Q1 2022 and 16 closed out, a net change of +1 holder.
- The largest Nautilus Biotechnolgy buyer in Q1 2022 was Vanguard Group, an estimated $4.38M added.
- The largest Nautilus Biotechnolgy seller in Q1 2022 was RA Capital Management, an estimated $12.6M sold.
Based on aggregated 13F filings for Q1 2022.